



Universiteit
Leiden
The Netherlands

Affinity-based profiling of the adenosine receptors

Beerkens, B.L.H.

Citation

Beerkens, B. L. H. (2023, November 9). *Affinity-based profiling of the adenosine receptors*. Retrieved from <https://hdl.handle.net/1887/3656497>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3656497>

Note: To cite this publication please use the final published version (if applicable).

Chapter 5

Development of an Affinity-Based Probe to Profile Endogenous Human Adenosine A₃ Receptor Expression

Bert L. H. Beerkens, Inge M. Snijders, Joep Snoeck, Rongfang Liu, Anton T. J. Tool, Sylvia E. Le Dévédec, Willem Jespers, Taco W. Kuijpers, Gerard J.P. van Westen, Laura H. Heitman, Adriaan P. IJzerman, and Daan van der Es

Abstract

The adenosine A₃ receptor (A₃AR) is a G protein-coupled receptor (GPCR) that exerts immunomodulatory effects in pathophysiological conditions such as inflammation and cancer. Thus far, studies towards the downstream effects of A₃AR activation have yielded contradictory results, thereby motivating the need for further investigations. Various chemical and biological tools have been developed for this purpose, ranging from fluorescent ligands to antibodies. Nevertheless, these probes are limited by their reversible mode of binding, relatively large size and often low specificity. Therefore, in this work, we have developed a clickable and covalent affinity-based probe (AfBP) to target the human A₃AR. Herein, we show validation of the synthesized AfBP in radioligand displacement, SDS-PAGE and confocal microscopy experiments, as well as utilization of the AfBP for the detection of endogenous A₃AR expression in flow cytometry experiments. Ultimately, this AfBP will aid future studies towards the expression and function of the A₃AR in pathologies.

J Med Chem **2023**, 66, 11399-11413.

Introduction

Adenosine is a signaling molecule that is the endogenous agonist to four adenosine receptors (ARs): the A₁, A_{2A}, A_{2B} and A₃ adenosine receptors (A₁AR, A_{2A}AR, A_{2B}AR and A₃AR) that are members of the larger G protein-coupled receptor (GPCR) family.^[1–3] Activation of the ARs via binding of adenosine induces a cascade of intracellular signaling pathways, that in turn modulate the cellular response to physiological and pathophysiological conditions, examples being inflammation, autoimmune disorders and cancers.^[4–6] The ARs are expressed on diverse cell and tissue types, in which the receptors all exert their own functions.^[1] In case of the human A₃AR (hA₃AR), the receptor has been found expressed on granulocytes: eosinophils, neutrophils and mast cells, among other cell types.^[7–10] Here, activation of the hA₃AR leads to various immunomodulatory effects, ranging from degranulation to influencing chemotaxis.^[7–13] However, multiple contradictory observations have been reported regarding the activation of hA₃ARs. For example, both inhibition and promotion of chemotaxis have been observed upon addition of a selective hA₃AR agonist to neutrophils.^[11,13,14] Next to that, expression of the hA₃AR is species-dependent, and large differences in hA₃AR activity have been found between humans and rodents.^[15,16] Thus, many questions regarding activity and functioning of the hA₃AR, whether on granulocytes or on other cell types and tissues, remain unanswered.

Most of the aforementioned studies have been carried out using selective ligands, e.g. agonists or antagonists to induce a cellular response as read-out. This has yielded valuable information on a biological level but ignores multiple factors that influence receptor signaling on a molecular level, such as receptor localization, protein-protein interactions (PPIs) and post-translational modifications (PTMs).^[17] Traditionally, these aspects would be studied using antibodies. However, antibodies for GPCRs are hindered in their selectivity due to the low expression levels of GPCRs and the high conformational variability of extracellular epitopes on GPCRs.^[18] This is especially true for the ARs that are lacking an extended extracellular N-terminus.

In the past decade, multiple small molecules have been developed as tool compounds to study the hA₃AR on a molecular level. Most prominently developed are the fluorescent ligands: agonists or antagonists conjugated to a fluorophore.^[19–28] Noteworthy, one of these fluorescent ligands has been used to study internalization, localization and certain PPIs of the hA₃AR on hA₃AR-overexpressing Chinese hamster ovary (CHO) cells, as well as activated neutrophils.^[12,24] Yet, the current use of fluorescent ligands is limited to the type of fluorophore conjugated, a fluorescent read-out in specific assay types and reversible binding to the receptor. Therefore, in this study, we aimed to develop a clickable affinity-based probe (AfBP) to broaden the current possibilities to measure and detect the receptor.

AfBPs are tool compounds that consist of three parts. Firstly, an electrophilic group ('warhead') is incorporated, that ensures covalent binding of the AfBP to the receptor (Figure 1).^[29,30] This allows usage of the probe in biochemical assays that rely on denaturation of proteins (e.g. SDS-PAGE and chemical proteomics). The warhead is coupled to a high affinity scaffold (the second part) that induces selectivity to the protein target of interest and thirdly, a detection moiety is introduced. Our lab has recently reported the development of electrophilic antagonist LUF7602 as an irreversible ligand of the hA₃AR (Figure S1).^[31] This compound contains two out of three functionalities of an AfBP, the only part missing being the detection moiety. Here, we introduced an alkyne group as ligation handle, that can be 'clicked' to a detection moiety through the Copper-catalyzed Alkyne-Azide Cycloaddition (CuAAC).^[32,33] Together this approach results in a 'modular' probe that can be clicked *in situ* to any detection moiety of interest. The new probe allows specific detection of overexpressed hA₃AR in various assay types, such as SDS-PAGE and confocal microscopy, as well as detection of endogenous hA₃AR in flow cytometry experiments on granulocytes.





Figure 1. Strategy to label the hA₃AR with an AfBP. First, the AfBP is added to cells or membrane fractions to allow irreversible bond formation between receptor and probe. Click reagents are then added to install a detection moiety onto the probe-bound receptor. Lastly, cells are further processed for detection, dependent on the detection method of interest. The image of the hA₃AR was generated using Protein Imager,^[34] using the structure of the hA₃AR (AF-P0DMS8-F1) as predicted by AlphaFold.^[35,36]

Results and Discussion

DESIGN AND SYNTHESIS

As mentioned in the introduction, a functional AfBP consists of three parts: warhead, pharmacological scaffold, and detection moiety. We decided on an alkyne moiety, to enable click-based incorporation of a detection moiety of choice onto the AfBP. Similar click strategies have already been used in the synthesis of fluorescent ligands for the hA₃AR.^[20,21,26,27,37] These ligands are however all lacking the electrophilic warhead. Additionally, contrary to those studies, we mainly performed the click reaction after binding of the AfBP to the receptor, preventing a loss of affinity due to bulky substituents. Such an approach has recently successfully been applied for the detection of other adenosine receptors, namely the A₁AR and A_{2A}AR.^[38–40] Also a non-selective AfBP for the hA₃AR has been reported, albeit without successful detection experiments.^[38] In previous studies we observed that the position of the alkyne moiety on the scaffold can greatly influence the affinity of the AfBP towards the receptor, thereby affecting the functionality of the AfBP.^[39] To increase the chances of obtaining a successful AfBP, we therefore introduced the alkyne group on three divergent locations onto the scaffold of LUF7602 (Scheme 1).

All three synthetic routes started with compound **1**, a high affinity selective antagonist for the hA₃AR reported over two decades ago.^[41] First, **1** was alkylated with bromopropane yielding tricyclic compound **2**. The benzylic moiety was then removed using palladium over carbon and an excess of NH₄HCO₂.^[31] The secondary amine of **3** was alkylated with alkyne-containing fluorosulfonyl moiety **4**, synthesized as recently described,^[39] to yield compound **5** (LUF7930) as the first out of three AfBPs. For the second AfBP, the secondary amine of **3** was alkylated by a protected propylamine, followed by deprotection of the Boc-group to yield compound **7**. The methoxy group of **7** was removed using BBr₃, yielding a zwitterionic intermediate that, after removal of remaining BBr₃, was used immediately in a peptide coupling to synthesize fluorosulfonyl derivative **8**. The alkyne moiety was then substituted onto the phenolic OH to yield compound **9** (LUF7960) as the second out of three AfBPs. For the last AfBP, the benzyl group of compound **1** was removed in the first step. However, synthesis and purification of **10** turned out to be cumbersome. Therefore a crude mixture of **10** was used in the following alkylation step, resulting in a poor but sufficient yield of compound **11**. The alkyne moiety was then substituted onto compound **11** using propargyl bromide, followed by deprotection of the Boc-group to yield compound **12**. Lastly, fluorosulfonyl benzoic acid was introduced using peptide coupling conditions, yielding compound **13** (LUF7934) as the final out of three AfBPs.



Scheme 1 Synthesis of hA₃AR-targeting affinity-based probes. Reagents and conditions: a) diazabicycloundecene (DBU), 1-bromopropane, MeCN, 70 °C, 1 h, quant.; b) Pd(OH)₂/C, NH₄HCO₂, EtOH, 80 °C, 7 days, 53%; c) K₂CO₃, DMF, rt, overnight, 29%; d) *tert*-butyl (3-bromopropyl)carbamate, K₂CO₃, DMF, 100 °C, 2 h, 97%; e) TFA, CHCl₃, 60 °C, overnight, 90%; f) (i) BBr₃ 1 M in DCM, CHCl₃, 50 °C, 6 days; (ii) 4-fluorosulfonyl benzoic acid, EDC·HCl, DIPEA, DMF, rt, two days, 13% over two steps; g) propargyl bromide (80% in toluene), K₂CO₃, DMF, rt, overnight, 30%; h) Pd(OH)₂/C, NH₄HCO₂, EtOH, 80 °C, 7 days; i) *tert*-butyl (3-bromopropyl)carbamate, K₂CO₃, DMF, 0-40 °C, 6 days, 25%; j) (i) propargyl bromide (80% in toluene), DBU, MeCN, rt, overnight; (ii) TFA, DCM, rt, 2 h, 67%; k) 4-fluorosulfonyl benzoic acid, EDC·HCl, DIPEA, DMF, rt, 3 h, 13%.

AFFINITY AND SELECTIVITY TOWARDS THE hA₃AR

The affinity of the synthesized AfBPs was determined in radioligand binding experiments. First, single concentration displacement assays were carried out on all four human adenosine receptors, using a final probe concentration of 1 μM (Table 1). Over 90% displacement was observed on the hA₃AR, while all probes showed minimal displacement (≤25%) of radioligand on the other ARs. This indicates good selectivity towards the hA₃AR over the other human ARs, a trend that was also observed in case of the parent compound.^[31] Next, the ‘apparent’ affinities (depicted as pK_i values) towards the hA₃AR were determined using full curve displacement assays. To study the presumable covalent mode of action, the apparent affinity was determined with (pre-4h) and without (pre-0h) four hours of pre-incubation of AfBP with hA₃AR, prior to addition of radioligand. The three synthesized AfBPs show very similar affinities at pre-0h with apparent pK_i values in the double digit nanomolar range (Table 2). In all three cases, the apparent pK_i shows a strong increase upon 4 h of pre-incubation, towards values in the single digit nanomolar range. This difference in affinity is reflected in a shift in apparent pK_i. Hence, substitution of an alkyne moiety at all three of the divergent positions is well tolerated in case of binding affinity. To investigate the binding mode of the probes within the orthosteric binding pocket, covalent docking experiments were performed using the previously determined nucleophile Y265 as anchor (Figure 2).^[31] All three compounds show a hydrogen bond interaction with the conserved N250 and π-π stacking with Phe168, two well-known interactions in ligand recognition in adenosine receptors.^[42] Thus, the alkyne substitution seems to be well tolerated for all three of the probes, thereby supporting the outcome of the radioligand displacement experiments. To further confirm the covalent mode of action, wash-out experiments were performed. Compounds **5**, **9** and **13** all showed to bind persistently to the hA₃AR, while full recovery of radioligand binding was observed in case of the reversible control compound LUF7714 (Figure 3, Figure S1).^[31] Altogether, this indicates that the three synthesized AfBPs bind covalently to the hA₃AR.

Table 1. Radioligand displacement (%) of the synthesized hA₃AR probes on the four adenosine receptors.

Compound	hA ₁ AR ^[a]	hA _{2A} AR ^[b]	hA _{2B} AR ^[c]	hA ₃ AR ^[d]
5 (LUF7930)	2 (3, 0)	0 (0, 0)	10 (22, -2)	95 (96, 94)
9 (LUF7960)	21 (24, 18)	7 (11, 2)	1 (0, 2)	95 (94, 96)
13 (LUF7934)	25 (24, 26)	8 (9, 7)	5 (4, 5)	92 (90, 93)

[a] % specific [³H]DPCPX displacement by 1 μ M of respective probe on CHO cell membranes stably expressing the human A₁AR (hA₁AR); [b] % specific [³H]ZM241385 displacement by 1 μ M of respective probe on HEK293 cell membranes stably expressing the human A_{2A}AR (hA_{2A}AR); [c] % specific [³H]PSB-603 displacement by 1 μ M of respective probe on CHO-spap cell membranes stably expressing the human A_{2B}AR (hA_{2B}AR); [d] % specific [³H]PSB-11 displacement at 1 μ M of respective probe on CHO cell membranes stably expressing hA₃AR. Probes were co-incubated with radioligand for 30 min at 25 °C. Data represent the mean of two individual experiments performed in duplicate.

Table 2. Time-dependent apparent affinity values of the synthesized hA₃AR probes.

Compound	pK _i (pre-0h) ^[a]	pK _i (pre-4h) ^[b]	Fold change ^[c]
5 (LUF7930)	7.55 $\pm$ 0.01	8.52 $\pm$ 0.05****	9.5 $\pm$ 1.0
9 (LUF7960)	7.27 $\pm$ 0.07	8.40 $\pm$ 0.03****	13.5 $\pm$ 1.2
13 (LUF7934)	7.17 $\pm$ 0.04	8.38 $\pm$ 0.05****	16.6 $\pm$ 3.5

[a] Apparent affinity determined from displacement of specific [³H]PSB-11 binding on CHO cell membranes stably expressing the hA₃AR at 25 °C after 0.5 h of co-incubating probe and radioligand. [b] Apparent affinity determined from displacement of specific [³H]PSB-11 binding on CHO cell membranes stably expressing the hA₃AR at 25 °C after 4 h of pre-incubation with the respective probe, followed by an additional 0.5 h of co-incubation with radioligand. [c] Fold change determined by ratio K_i(0 h)/K_i(4 h). Data represent the mean $\pm$ SEM of three individual experiments performed in duplicate. **** p < 0.0001 compared to the pK_i values obtained from the displacement assay with 0 h pre-incubation of probe, determined by a one-way ANOVA test using multiple comparisons.




Figure 2. Putative binding modes of compounds 5 (panel A), 9 (panel B) and 13 (panel C). All three compounds show a hydrogen bond interaction with the conserved N250 and π - π stacking with Phe168, two well-known interactions in ligand recognition in adenosine receptors.^[42] The alkyne group, indicated with an arrow in each panel, fits into the binding pocket on each exit vector, and the binding orientation of the core compound, as published previously by our group, is maintained.^[31]




Figure 3. Wash-out assay reveals covalent binding of all three probes to the hA₃AR. CHO cells membranes stably transfected with the hA₃AR were pre-incubated with 1% DMSO (vehicle), 1 μ M of non-covalent control compound (LUF7714) or 1 μ M of compounds **5** (LUF7930), **9** (LUF7960) or **13** (LUF7934). The samples were washed for either 0 or 4 times, before being exposed to [³H]PSB-11 in a radioligand displacement assay. Data is expressed as the percentage of the vehicle group (100%) and represents the mean $\pm$ SEM of three individual experiments performed in duplicate. **** $p < 0.0001$ determined by a two-way ANOVA test using multiple comparisons.

LABELING OF THE hA₃AR IN SDS-PAGE EXPERIMENTS

Next, the potential AfBPs were investigated on their ability to label the hA₃AR in SDS-PAGE experiments. Membrane fractions with stable expression of the hA₃AR were incubated for 1 h with 50 nM (roughly the apparent K_i) of AfBPs **5**, **9** or **13**, subjected to click ligation with a Cy5-fluorophore, denatured and resolved by SDS-PAGE. Pre-incubation with the hA₃AR-selective antagonist PSB-11 was used as negative control,^[43] and an extra incubation step with PNGase was introduced to remove N-glycans.^[39] Detection of labeled hA₃AR turned out to be difficult if not deglycosylated: the receptor appeared as a smear at about 70 kDa (Figure 4A and 5A). Yet, this mass corresponds to the band of rat A₃AR as has been shown in SDS-PAGE experiments on overexpressing CHO cells.^[44,45] N-deglycosylation of the mixture of membrane proteins revealed a protein band at ± 30 kDa in case of all three AfBPs. This protein was not labeled after pre-incubation with reversible antagonist PSB-11 and is therefore most likely the hA₃AR. To select one of these AfBPs for further labeling studies, the intensities of the bands at ± 30 kDa were compared between the probes (Figure 4B), but no significant differences were found. Correspondingly, the alkyne groups do not inflict any strong unfavorable interactions upon covalent docking of the compounds in the hA₃AR model (Figure 2). Examination of the amount of off-target labeling instead indicated there are fewer other proteins labeled by **9** (LUF7960) than by the other two probes **5** and **13** (Figure 4A). Therefore we decided to continue our subsequent experiments with AfBP **9** (LUF7960). Further control experiments were performed: labeling in CHO membrane fractions without expression of the hA₃AR, no addition of probe and clicking without copper or Cy5-N₃ (Figure 4C). The band at ± 30 kDa was not observed in any of the control lanes, confirming that this band is the hA₃AR. Notably, we did not observe any hA₃AR-specific labeling by a commercially available hA₃AR antibody in Western Blot experiments (Figure S2). Presumably the selectivity and affinity of antibodies is compromised by the relatively short N-terminus and extracellular loops of the hA₃AR.




Figure 4. Labeling of the hA₃AR by the synthesized affinity-based probes. (A) Labeling of proteins by **5** (LUF7930), **9** (LUF7960) and **13** (LUF7934). Membrane fractions from CHO cells stably overexpressing the hA₃AR were pre-incubated for 30 min with antagonist (PSB-11, 1 μ M final concentration) or 1% DMSO (control), prior to incubation for 1 h with the respective probe (50 nM final concentration). The proteins were subjected to PNGase or MilliQ (control) for 1 h to remove N-glycans. Samples were then clicked to Cy5-N₃ (1 μ M final concentration), denatured using Laemmli buffer (4x) and resolved by SDS-PAGE. Gels were imaged using in-gel fluorescence and stained with Coomassie Brilliant Blue (CBB) as protein loading control. (B) Quantification of the lower hA₃AR band ($\pm$ 30 kDa). The band intensities were taken and corrected for the observed amount of protein per lane upon CBB staining. The band at 55 kDa of the PageRuler Plus ladder (not shown) was set to 100% for each gel and band intensities were calculated relative to this band. The mean values $\pm$ SEM of three individual experiments are shown. Significance was calculated using a one-way ANOVA test using multiple comparisons (ns = not significant). (C) Control experiments with probe **9** (LUF7960). Membrane fractions from CHO cells with or without (first lane) stable expression of the hA₃AR were pre-incubated for 30 min with antagonist (PSB-11, 1 μ M final concentration) or 1% DMSO (control), prior to incubation for 1 h with **9** (LUF7960) (50 nM final concentration) or 1% DMSO (control). Proteins were deglycosylated with PNGase for 1 h. Click mix was then added, containing CuSO₄ or MilliQ (control) and Cy5-N₃ (1 μ M final concentration) or DMSO (control). The samples were then denatured with Laemmli buffer (4x) and resolved by SDS-PAGE. Gels were imaged using in-gel fluorescence and afterwards stained with CBB. The image shown is a representative of three individual experiments.

LABELING OF hA₃AR ON LIVE CHO CELLS

Having confirmed binding and labeling of the hA₃AR in CHO membrane fractions, we moved towards labeling experiments on live CHO cells stably expressing the hA₃AR. Live cells were incubated with 50 nM of AfBP **9** (LUF7960), prior to processing for either SDS-PAGE or microscopy experiments. In case of SDS-PAGE experiments, membranes were collected, the probe-bound proteins clicked to a Cy5-fluorophore, denatured and resolved by SDS-PAGE. This yielded ‘cleaner’ gels as compared to labeling in membrane fractions: no strong off-target bands were observed (Figure 5). The smear of glycosylated hA₃AR at $\pm$ 70 kDa is now better visible (Figure 5A) and absent in the control lanes (no hA₃AR, no AfBP or pre-incubation with PSB-11). Similar to the experiments on cell membranes, a strong reduction in size of the band is observed upon pre-incubation with PNGase (Figure 5B). Both signals were significantly reduced by pre-incubation with PSB-11 (Figure 5C-D). Thus, AfBP **9** (LUF7960) also binds and labels the hA₃AR on live cells. We speculate that the increased amount of off-target labeling in membrane fractions is due to the high enrichment of subcellular membrane proteins. Together with the electrophilic nature of the AfBP, this can result in an increased amount of protein labeling, as we have observed in our experiments using an electrophilic A₁AR probe (chapter 4).^[39]




Figure 5. Labeling of the hA₃AR on live CHO cells. CHO cells with or without (first lane) stable expression of the hA₃AR were pre-incubated for 1 h with antagonist (PSB-11, 1 μ M final concentration) at 37 $^{\circ}$ C, prior to incubation with **9** (LUF7960) (50 nM final concentration) for 1 h at 37 $^{\circ}$ C. After the incubation, unbound probe was washed away with PBS. Membranes were prepared, brought to a concentration of 1 μ g/ μ L and subjected to the click reaction with Cy5-N₃ (1 μ M final concentration). Samples were then denatured with Laemmli buffer (4x), resolved by SDS-PAGE and imaged using in-gel fluorescence. Gels were stained by Coomassie Brilliant Blue (CBB) as loading control. (A) Labeling of glycosylated hA₃AR. (B) Labeling of deglycosylated hA₃AR. PNGase was added prior to the addition of click reagents. (C-D) Quantification of the observed signals with and without addition of antagonist (PSB-11). The band intensities were calculated using ImageLab and corrected for the amount of protein measured after CBB staining. The band at 55 kDa of the PageRuler Plus ladder (not shown) was set to 100% for each gel and band intensities were calculated relative to this band. The mean values $\pm$ SEM of three individual experiments are shown. Significance was calculated by a two-way ANOVA test using multiple comparisons (*** $p < 0.001$; ** $p < 0.01$).

In case of the microscopy experiments, cells were fixed after probe incubation, followed by a click reaction with TAMRA-N₃, multiple washing steps and staining of the cellular nuclei with DAPI prior to confocal imaging. A strong increase in TAMRA intensity was observed at the cell membranes upon addition of probe to the wells (Figure 6A), visible by the increase in signal at cell-cell contacts. This signal was reduced by pre-incubation with PSB-11 and was absent for CHO cells not expressing the hA₃AR (Figure 6B-C). We therefore conclude that labeling of overexpressed hA₃AR by **9** (LUF7960) on living CHO cells can be studied by both SDS-PAGE and confocal microscopy experiments. Multiple fluorescent ligands have already been verified in similar fluorescence microscopy assays.^[19,21–24,28] Together these fluorescent ligands comprise a molecular ‘toolbox’ that allows extensive characterization of the hA₃AR in microscopy assays, as well as localization and internalization (with fluorescent agonists) of the receptor.^[12,24] The introduction of an electrophilic warhead and clickable handle on probe **9** (LUF7960) extends the possibilities to study the hA₃AR in microscopy assays, e.g. by allowing workflows that are dependent on thorough washing steps and/or denaturation of proteins.




Figure 6. Labeling of the hA₃AR observed by confocal microscopy. CHO cells with (CHO-hA₃AR) or without (CHO-K1) stable expression of the hA₃AR were pre-incubated for 30 min with PSB-11 (1 μM final concentration) or 1% DMSO (control) and incubated for 60 min with **9** (LUF7960) or 1% DMSO (vehicle control). Cells were fixed, permeabilized and clicked to TAMRA-N₃ as fluorophore (1 μM final concentration). The cells were then washed and kept in PBS containing 300 nM DAPI during confocal imaging. (A) Shown are DAPI staining (blue, first row), TAMRA staining (yellow, second row) and an overlay of both stains (third row). Images were acquired automatically at multiple positions in the well of interest and are representatives from two biological experiments. Scale bar = 50 μM. Figure was created using OMERO.^[46] (B) Comparison of the integrated fluorescence intensity between treatment conditions. Data was obtained from 2x9 fields of view, from the same experiment performed in duplicate. Each data point represents the integrated fluorescent intensity of the TAMRA signal per individual cell. Shown in the bar graph is the average integrated fluorescence intensity of all individual cells ± SEM. Significance was calculated using a one-way ANOVA test using multiple comparisons. A significant increase in intensity is observed for the cells containing the hA₃AR and treated with **9** (LUF7960), versus the other conditions.

LABELING OF ENDOGENOUS hA₃AR IN FLOW CYTOMETRY EXPERIMENTS

Having established the potential of **9** (LUF7960) in overexpressing cell systems, we turned to native hA₃AR expression in flow cytometry experiments in order to cope with expected low levels of observable fluorescence after receptor labeling caused by the notoriously low expression levels of GPCRs. Similar usage of fluorescent probes in flow cytometry experiments have thus far led to kinetic studies of ligand binding,^[20,27] and detection of the hA₃AR on the HL-60 model cell line.^[21] In order to establish an assay setup for primary cells we first used CHO cells as a model system. To avoid the use of excess copper on live cells, AfBP **9** (LUF7960) was first clicked to a Cy5-fluorophore and desalted, before being incubated for 1 h with living CHO cells with or without stable expression of the hA₃AR. Unbound probe was removed by washing steps and cells were analyzed by flow cytometry. The two types of CHO cells (+/- hA₃AR) showed a difference in Cy5 mean fluorescence intensity (MFI), i.e.: hA₃AR-expressing CHO cells showed a significant increase in Cy5 MFI upon probe labeling, which was absent for CHO cells without hA₃AR (Figure 7A-B). Next to that, pre-incubation with PSB-11 significantly reduced the observed signal in case of the hA₃AR-expressing CHO cells (Figure 7A-B), indicating that the observed signal is hA₃AR-specific. Noteworthy, no significant labeling was observed with a commercially available fluorophore-conjugated hA₃AR antibody.




Figure 7. Labeling of the hA₃AR in flow cytometry experiments. Samples were pre-incubated for 30 min with the antagonist PSB-11 and incubated for 60 min with **9** (LUF7960) pre-clicked to a Cy5 fluorophore (**9**-Cy5). Samples were then washed and analyzed on Cy5 fluorescence by flow cytometry. (A) Cy5 mean fluorescence intensity (MFI) in CHO cells with (CHO-hA₃AR) and without (CHO-K1) stable expression of the hA₃AR. Values represent the mean $\pm$ SEM of three individual experiments performed in duplicate. Significance was calculated by a one-way ANOVA test using multiple comparisons (*** p < 0.001; ** p < 0.01; ns = not significant). (B) Representative graph showing the observed shift in MFI related to hA₃AR labeling in CHO-hA₃AR cells. (C) MFI of **9**-Cy5 in neutrophils and eosinophils purified from human blood samples. Values represent the mean $\pm$ SEM (n=4) of four donors from two individual experiments. Significance was calculated by a one-way ANOVA test using multiple comparisons (**** p < 0.0001; *** p < 0.001; ns = not significant). (D) Representative graph showing the observed shift in MFI related to hA₃AR labeling in human eosinophils.

Next we used the optimized procedure for further investigation of hA₃AR expression on human granulocytes. Eosinophils and neutrophils were purified from human blood samples obtained from four donors, subjected to Cy5-clicked AfBP **9** (LUF7960) and analyzed by flow cytometry. Within these experiments, purified neutrophils did not show a significant increase in Cy5 MFI upon incubation with probe (Figure 7C). The purified eosinophils however, showed a significant increase in MFI that was reduced upon pre-incubation with the antagonist PSB-11 (Figure 7C-D). Thus, with the aid of AfBP **9** (LUF7960) we were able to selectively detect hA₃AR expression on human eosinophils, but not on human neutrophils. In the past hA₃AR expression has been observed on both human eosinophils and neutrophils,^[7-9,12-14] though the basal hA₃AR expression levels on human neutrophils were low in comparison to the expression on stimulated neutrophils.^[12,13] Correspondingly, the herein investigated neutrophils showed little to no hA₃AR expressed on the cell surface.

Future studies that make use of AfBP **9** (LUF7960) might therefore yield new information on hA₃AR expression levels on stimulated neutrophils, among other leukocytes. Furthermore, the role of the hA₃AR in inflammatory conditions, such as asthma, ischemic injury and sepsis,^[47–49] might be elucidated using AfBP **9** (LUF7960) as tool to detect receptor expression.

Conclusion

In this work, we have synthesized and evaluated three affinity-based probes **5**, **9** and **13**, that are all shown to bind covalently and with similar apparent affinities to the hA₃AR. Although all three probes were able to label the hA₃AR in SDS-PAGE experiments, we decided to continue with **9** (LUF7960) due to the low number of off-target protein bands detected on gel. We show that AfBP **9** (LUF7960) is a versatile AfBP that can be used together with different fluorophores, examples in this study being Cy5 and TAMRA. The combination of **9** (LUF7960) with click chemistry allowed us to label the hA₃AR in various assay types, such as SDS-PAGE, confocal microscopy and flow cytometry experiments, on both model cell lines and cells derived from human blood samples. In our hands, **9** (LUF7960) showed to be successful in the selective labeling of the hA₃AR, while commercial antibodies were not. We therefore believe that probe **9** (LUF7960) will be of great use in the detection and characterization of the hA₃AR in different types of granulocytes, among other cell types.

Acknowledgements

We thank I. Boom (LACDR, Leiden, The Netherlands) for performing high-resolution mass spectrometry measurements and B. Slütter (LACDR, Leiden, The Netherlands) for flow cytometry. We also thank the Leiden University Cell Observatory for access to the confocal microscope and support and assistance in this work.

Supplementary Figures




Figure S1. A₃AR ligands used in this study: covalent antagonist LUF7602, reversible control LUF7714 and antagonist PSB-11.^[31,43]




Figure S2. Labelling of the hA₃AR is evident in SDS-PAGE, but not in western blot experiments. (A) A specific hA₃AR band (lane 6) is observed upon measuring in-gel fluorescence after protein labelling by AfBP 9 (LUF7960); (B) No specific hA₃AR band is observed upon measuring chemiluminescence after protein labelling by the commercially available antibody, i.e.: the labelled proteins appear in both membrane fractions with and without (lane 1) expression of the hA₃AR. (A-B) Membrane fractions from CHO cells with and without (first lane) overexpression of the hA₃AR were pre-incubated for 30 min with the selective antagonist PSB-11 or 1% DMSO (vehicle control), prior to incubation for 1 h with AfBP 9 (LUF7960). *N*-Glycans were removed using PNGase, probe-bound proteins clicked to Cy5-N₃, denatured using Laemmli buffer and subjected to SDS-PAGE. The gel was imaged using in-gel fluorescence (Figure A) and subsequently transferred to 0.2 μm PVDF blots (Bio-Rad) using a Bio-Rad Trans-Blot Turbo system (2.5 A, 7 min). The blot was blocked in 5% BSA in TBST (1 h, rt) and subjected to primary antibody (rabbit hA₃AR) 1: 10.000 in 1% BSA in TBST (overnight, 4 °C). The blot was washed (3 x TBST), subjected to secondary antibody (goat rabbit-HRP) 1:2.000 in 1% BSA in TBST (1 h, rt), washed again (2 x TBST, 1 x TBS), activated with luminol enhancer and peroxide (3 min, rt, dark) and subsequently scanned on fluorescence (Figure A) and chemiluminescence (Figure B). Images are representatives of three individual experiments.






Figure S3. Gating strategy during analysis of the flow cytometry data. CHO-A₃AR (A) and CHO-K1 (B) cells were selected based on population density using SSC-A vs FSC-A gating and possible doublets were removed using FSC-H vs FSC-A gating. Neutrophils (C) and eosinophils (D) were selected based on population density using SSC-A vs FSC-A gating and PE signal of the PE-conjugated Siglec-8 antibody (selective marker for eosinophils) using PE-A vs APC-A gating. Q4 (neutrophils) and Q1 (eosinophils) were further analyzed on Cy5 intensity (APC channel).

Experimental

Chemistry


All reactions were carried out using commercially available reagents, unless noted otherwise. Reagents and solvents were purchased from Sigma-Aldrich (Merck), Fisher Scientific or VWR chemicals. All reactions were carried out under an N₂ atmosphere in oven-dried glassware. Reactions were monitored by thin layer chromatography (TLC) using TLC Silica gel 60 F254 plates (Merck) and UV irradiation (254 or 366 nm) as detection method. ¹H, ¹³C and ¹⁹F NMR spectra were recorded on a Bruker AV-300 (300 MHz), Bruker AV-400 (400 MHz) or Bruker AV-500 (500 MHz) spectrometer. Chemical shift values are reported in ppm (δ) using tetramethylsilane (TMS) or solvent resonance as internal standard. Coupling constants (*J*) are reported in Hz and multiplicities are indicated by s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), p (pentuplet), h (hexuplet) or m (multiplet). Compound purity was determined by LC-MS, using the LCMS-2020 system (Shimadzu) coupled to a Gemini® 3 μm C18 110Å column (50 x 3 mm). In short, compounds were dissolved in H₂O:Acetonitrile (MeCN):*t*-BuOH 1:1:1, injected onto the column and eluted with a linear gradient of H₂O:MeCN 90:10 + 0.1% formic acid → H₂O:MeCN 10:90 + 0.1% formic acid over the course of 15 minutes. High-resolution mass spectrometry (HRMS) was performed on a X500R QTOF mass spectrometer (SCIEX).

Synthesis of 5 (LUF7930)



1-Benzyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (1)


Compound 1 was synthesized in our lab as previously reported.^[31]



1-Benzyl-8-methoxy-3-propylpyrido[2,1-f]purine-2,4(1H,3H)-dione (2)


1 (7.37 g, 22.9 mmol, 1.0 eq) was dissolved in acetonitrile (145 mL) and diazabicycloundecene (DBU) (9.58 mL, 64.1 mmol, 2.8 eq) and 1-bromopropane (6.30 mL, 68.6 mmol, 3.0 eq) were added. The mixture was stirred for 1 h at 70 °C and cooled with ice overnight. The solvent was then removed under vacuum. The residue was filtered and washed with H₂O, EtOH and Et₂O and further dried under vacuum. This yielded **2** (quant., 8.33 g, 22.9 mmol) as a white solid.

TLC (DCM:MeOH 98:2): R_f = 0.88. **¹H NMR** (400 MHz, (CD₃)₂SO): δ [ppm] = 8.81 (d, J = 7.4 Hz, 1H), 7.43 – 7.38 (m, 2H), 7.35 (t, J = 7.3 Hz, 2H), 7.33 – 7.26 (m, 2H), 6.98 (dd, J = 7.4, 2.6 Hz, 1H), 5.29 (s, 2H), 3.94 (s, 3H), 3.91 (t, J = 7.4 Hz, 2H), 1.63 (h, J = 7.5 Hz, 2H), 0.91 (t, J = 7.5 Hz, 3H). **¹³C NMR** (101 MHz, (CD₃)₂SO): δ [ppm] = 162.2, 154.6, 151.8, 150.5, 137.7, 129.4, 128.7, 128.4, 128.3, 108.8, 101.0, 96.7, 57.2, 46.9, 42.9, 21.9, 12.1.




8-Methoxy-3-propylpyrido[2,1-f]purine-2,4(1H,3H)-dione (3)

2 (4.04 g, 11.1 mmol, 1.0 eq), Pd(OH)₂/C (4.05 g, 28.8 mmol, 2.6 eq) and ammonium formate (0.72 g, 11.4 mmol, 1.0 eq) were suspended in EtOH (500 mL) and stirred at 80 °C under reflux conditions. Over the course of one week, 3 extra portions of ammonium formate (0.72 g, 11.4 mmol, 1.0 eq) were gradually added. The mixture was then cooled to rt and filtered over Celite. The residue was extracted with hot DMF and the filtrate was concentrated. The residue was purified by column chromatography (DCM:MeOH 98:2 → 90:10) to yield **3** (1.60 g, 5.82 mmol, 53 % yield) as a white solid. **TLC** (DCM:MeOH 95:5): R_f = 0.38. **¹H NMR** (400 MHz, (CD₃)₂SO): δ [ppm] = 12.05 (s, 1H), 8.74 (d, J = 7.4 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 6.90 (dd, J = 7.4, 2.5 Hz, 1H), 3.91 (s, 3H), 3.82 (t, J = 7.6 Hz, 2H), 1.63 – 1.52 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H). **¹³C NMR** (101 MHz, (CD₃)₂SO): δ [ppm] = 161.1, 154.5, 151.1, 150.5, 149.8, 127.5, 107.3, 95.4, 56.2, 41.0, 21.0, 11.2.



3-(4-(Fluorosulfonyl)-N-(prop-2-yn-1-yl)benzamido)propyl 4-methylbenzenesulfonate (4)

Compound **4** was synthesized in our lab as described in chapter 4.




4-((3-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride (5) (LUF7930)

To a solution of **3** (37 mg, 0.14 mmol, 1.0 eq), **4** (63 mg, 0.14 mmol, 1.0 eq) in dry DMF (1.5 mL) and K₂CO₃ (29 mg, 0.20 mmol, 1.5 eq) were added. The reaction stirred over two nights at rt. The mixture was diluted with EtOAc (5 mL) and washed with water (2 x 5 mL). The water layers were combined and extracted with EtOAc (2 x 10 mL). The organic layers were combined, dried with MgSO₄ and concentrated under reduced pressure. The crude product was purified with column chromatography (DCM:MeOH 98:2 → 95:5) to yield **5** (22 mg, 0.04 mmol, 29%) as a white solid. NMR measurements revealed the presence of two rotamers at 20 °C, but not at 100 °C. **TLC** (DCM:MeOH 98:2 + 1% Et₃N): R_f = 0.63. **¹H NMR** (500 MHz, (CD₃)₂SO, 20 °C): δ [ppm] = 8.74 (dd, J = 23.1, 7.2 Hz, 1H), 8.25 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 15.1 Hz, 1H), 6.95 (t, J = 7.9 Hz, 1H), 4.35 (s, 1H), 4.16 (t, J = 6.2 Hz, 1H), 4.03 (s, 1H), 3.91 (d, J = 10.1


Hz, 5H), 3.78 (t, $J = 6.8$ Hz, 1H), 3.60 (t, $J = 6.4$ Hz, 1H), 3.40 (s, 1H), 3.32 – 3.24 (m, 1H), 2.19 – 2.12 (m, 1H), 2.11 – 2.03 (m, 1H), 1.64 – 1.56 (m, 1H), 1.56 – 1.47 (m, 1H), 0.86 (dt, $J = 23.2, 7.4$ Hz, 3H). **$^1\text{H NMR}$** (500 MHz, $(\text{CD}_3)_2\text{SO}$, 100°C): δ [ppm] = 8.79 (d, $J = 7.3$ Hz, 1H), 8.09 (d, $J = 7.8$ Hz, 2H), 7.74 (d, $J = 8.1$ Hz, 2H), 7.15 (d, $J = 2.7$ Hz, 1H), 6.94 (dd, $J = 7.4, 2.6$ Hz, 1H), 4.20 (s, 2H), 4.10 (d, $J = 5.3$ Hz, 2H), 3.95 (s, 3H), 3.90 (t, $J = 7.3$ Hz, 2H), 3.52 (s, 2H), 3.11 (s, 1H), 2.16 (p, $J = 6.6$ Hz, 2H), 1.63 (h, $J = 7.5$ Hz, 2H), 0.90 (t, $J = 7.5$ Hz, 3H). **$^{13}\text{C NMR}$** (126 MHz, $(\text{CD}_3)_2\text{SO}$, 20°C): δ [ppm] = 168.2, 167.9, 161.2, 153.7, 153.3, 150.9, 150.8, 150.5, 149.5, 149.4, 143.4, 132.4, 132.2, 132.0, 131.8, 128.9, 128.6, 128.3, 127.9, 127.7, 107.7, 100.1, 99.8, 95.6, 95.5, 79.3, 79.2, 75.9, 74.6, 56.2, 46.2, 42.8, 41.7, 40.7, 40.2, 38.8, 33.7, 26.9, 25.5, 20.9, 11.2. **$^{13}\text{C NMR}$** (126 MHz, $(\text{CD}_3)_2\text{SO}$, 100°C): δ [ppm] = 167.7, 160.9, 153.2, 151.6, 150.5, 149.1, 143.0, 132.2 (d, $J = 23.7$ Hz), 127.9, 127.7, 127.2, 107.0, 99.6, 95.4, 78.6, 74.3, 55.7, 41.4, 40.1, 25.8, 20.3, 10.4. **$^{19}\text{F NMR}$** (471 MHz, $(\text{CD}_3)_2\text{SO}$, 20°C): δ [ppm] = 67.08, 66.35. **$^{19}\text{F NMR}$** (471 MHz, $(\text{CD}_3)_2\text{SO}$, 100°C): δ [ppm] = 65.99. **HRMS** (ESI, m/z): $[\text{M}+\text{H}]^+$, calculated: 556.1661, found: 556.1628. **HPLC** 97%, RT 10.830 min.

Synthesis of 9 (LUF7960)




***Tert*-butyl (3-(8-methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-*f*]purin-1(2H)-yl)propyl)carbamate (6)**


3 (1.18 g, 4.3 mmol, 1.0 eq), *tert*-butyl (3-bromopropyl)carbamate (1.54 g, 6.5 mmol, 1.5 eq) and K_2CO_3 (890 mg, 6.5 mmol, 1.5 eq) were dissolved in DMF (60 mL) and refluxed at 100°C for 2 h. Afterwards the mixture was allowed to cool down to rt overnight. The next day, the solvents were removed by evaporation under reduced pressure. The residue was dissolved in chloroform (100 mL), washed with H_2O (3 x 100 mL), dried over MgSO_4 and concentrated under reduced pressure to yield **6** (1.80 g, 4.2 mmol, 97%) as a white solid. **TLC** (DCM:MeOH 99:1): $R_f = 0.76$. **$^1\text{H NMR}$** (300 MHz, CDCl_3): δ [ppm] = 8.82 (d, $J = 7.3$ Hz, 1H), 6.94 (d, $J = 2.5$ Hz, 1H), 6.75 (dd, $J = 7.4, 2.5$ Hz, 1H), 5.62 (s, 1H), 4.26 (t, $J = 6.2$ Hz, 2H), 4.01 (d, $J = 7.5$ Hz, 2H), 3.92 (s, 3H), 3.17 – 3.06 (m, 2H), 2.03 – 1.92 (m, 2H), 1.80 – 1.61 (m, 2H), 1.45 (s, 9H), 0.98 (t, $J = 7.4$ Hz, 3H). **$^{13}\text{C NMR}$** (75 MHz, CDCl_3): δ [ppm] = 161.8, 156.2, 154.7, 151.9, 150.1, 128.1, 107.9, 95.3, 79.1, 56.0, 42.9, 40.9, 37.2, 28.6, 21.6, 11.5.

**1-(3-Aminopropyl)-8-methoxy-3-propylpyrido[2,1-f]purine-2,4(1H,3H)-dione (7)**

TFA (12.8 mL, 166.6 mmol, 40.0 eq) was added to a solution of **6** (1.80 g, 4.2 mmol, 1.0 eq) in chloroform (40 mL) and the mixture was stirred at 60°C overnight. Afterwards, the pH was increased with 2M NaOH (50 mL) to a value of approx. 10. The aqueous layer was extracted with EtOAc (2 x 50 mL) dried over MgSO₄, filtered and concentrated under reduced pressure to yield **7** (1.25 g, 3.8 mmol, 90%) as a white solid. **TLC** (DCM:MeOH 90:10 + 1% NEt₃): R_f = 0.44. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 8.83 (dd, *J* = 7.3, 0.7 Hz, 1H), 6.95 (d, *J* = 1.9 Hz, 1H), 6.74 (dd, *J* = 7.4, 2.5 Hz, 1H), 4.29 (t, *J* = 6.7 Hz, 2H), 4.02 (t, *J* = 7.6 Hz, 2H), 3.92 (s, 3H), 2.74 (t, *J* = 6.5 Hz, 2H), 1.97 (p, *J* = 6.6 Hz, 2H), 1.71 (h, *J* = 7.4 Hz, 2H), 1.24 (t, *J* = 7.0 Hz, 2H), 0.98 (t, *J* = 7.4 Hz, 3H). **¹³C NMR** (101 MHz, CDCl₃): δ [ppm] = 161.6, 154.5, 151.5, 151.3, 149.9, 127.8, 107.6, 100.9, 95.1, 55.9, 42.6, 40.7, 38.8, 31.9, 21.4, 11.3.


**1-(3-Aminopropyl)-8-hydroxy-3-propylpyrido[2,1-f]purine-2,4(1H,3H)-dione (14)**

BBr₃ (1M solution in DCM) (30.2 mL, 30.2 mmol, 10 eq) was added to a solution of **7** (1.00 g, 3.0 mmol, 1.0 eq) in CHCl₃ (40 mL). The mixture was refluxed at 50 °C overnight. As the reaction was not complete (as determined by LC-MS) additional BBr₃ (1M solution in DCM) (30.2 mL, 30.2 mmol, 10 eq) was added and the mixture was refluxed for 5 days. The reaction was then cooled to rt, upon which H₂O (100 mL) was added dropwise to quench the reaction. The mixture was stirred for 1 h and afterwards the organic layer was removed. The aqueous layer was concentrated to yield crude **14**. This was used in subsequent reaction steps without further purification.

**4-((3-(8-Hydroxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)carbamoyl)benzenesulfonyl fluoride (8)**

4-Fluorosulfonyl benzoic acid (678 mg, 3.3 mmol, 1.1 eq) and EDC·HCl (868 mg, 4.5 mmol, 1.5 eq) were dissolved in dry DMF (10 mL) and stirred at rt. After one hour, the mixture was added to a solution of crude **14** (958 mg, 3.0 mmol, 1.0 eq) in dry DMF (20 mL). DIPEA (1.8 mL, 10.6 mmol, 3.5 eq) was added and the mixture was stirred overnight. The reaction was not completed by then (as indicated by LC-MS) and therefore additional 4-fluorosulfonyl benzoic acid (678 mg, 3.3 mmol, 1.1 eq) and EDC·HCl (868 mg, 4.5 mmol, 1.5 eq) were added. The mixture was stirred overnight and the next day DCM (150 mL) was added. The organic layer was washed with 1M HCl (2 x 200 mL), dried over MgSO₄, filtrated and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH 98:2 → 80:20) to yield **8** (194 mg, 0.4 mmol, 13% over two steps) as a white solid. **TLC** (DCM:MeOH 95:5): R_f = 0.45. **¹H NMR** (500 MHz, CDCl₃): δ [ppm] = 8.77 (d, *J* = 7.1 Hz, 1H), 8.69 (t, *J* = 6.2 Hz, 1H), 8.18 (d, *J* = 8.1 Hz, 2H), 8.06 (d, *J* = 8.1 Hz, 2H), 7.96 (m, 1H), 6.96 (s, 1H), 6.80 (d, *J* = 7.0 Hz, 1H), 4.27 (t, *J* = 5.9 Hz, 2H), 3.99 (t, *J* = 7.4 Hz, 2H), 3.44 (m, 2H),



2.10 (m, 2H), 1.68 (h, $J = 6.9$ Hz, 2H), 0.93 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3): δ [ppm] = 165.5, 161.0, 154.3, 151.9, 151.3, 150.2, 141.0, 135.3 (d, $J = 25.1$ Hz), 128.8, 128.6, 108.3, 100.9, 98.1, 43.0, 40.9, 36.4, 27.4, 21.5, 11.4. ^{19}F NMR (471 MHz, CDCl_3): δ [ppm] = 65.58.



4-((3-(2,4-Dioxo-8-(prop-2-yn-1-yloxy)-3-propyl-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)carbamoyl)benzenesulfonyl fluoride (**9**) (LUF7960)


A 80% v/v solution of propargyl bromide in toluene (0.42 mL, 0.4 mmol, 1.0 eq) was further diluted in dry DMF (4.2 mL) and added to a solution of **8** (194 mg, 0.4 mmol, 1.0 eq) in dry DMF (20 mL). K_2CO_3 (53 mg, 0.4 mmol, 1.0 eq) was added to the mixture, which was stirred overnight. The mixture was then diluted with EtOAc (80 mL) and the organic layer was washed with H_2O (2 x 100 mL) and brine (100 mL), dried over MgSO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (Pentane:EtOAc 3:7) to yield **9** (63 mg, 0.1 mmol, 30%) as a white solid. **TLC** (EtOAc): $R_f = 0.54$. ^1H NMR (500 MHz, CDCl_3): δ [ppm] = 8.91 (d, $J = 7.4$ Hz, 1H), 8.47 (t, $J = 6.3$ Hz, 1H), 8.27 (d, $J = 8.0$ Hz, 2H), 8.18 (d, $J = 8.5$ Hz, 2H), 7.03 (d, $J = 2.5$ Hz, 1H), 6.85 (dd, $J = 7.4, 2.5$ Hz, 1H), 4.82 (d, $J = 2.4$ Hz, 2H), 4.35 (t, $J = 5.8$ Hz, 2H), 4.09–4.02 (m, 2H), 3.46 (q, $J = 6.1$ Hz, 2H), 2.64 (t, $J = 2.4$ Hz, 1H), 2.16 (p, $J = 5.9$ Hz, 2H), 1.74 (h, $J = 7.5$ Hz, 2H), 1.00 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3): δ [ppm] = 164.8, 159.8, 154.5, 152.1, 151.4, 149.5, 141.6, 135.4 (d, $J = 29.1$ Hz), 128.9, 128.6, 128.4, 108.3, 101.3, 96.6, 77.7, 76.6, 56.6, 43.0, 40.8, 35.8, 27.6, 21.6, 11.5. ^{19}F NMR (471 MHz, CDCl_3): δ [ppm] = 65.76. **HRMS** (ESI, m/z): $[\text{M}+\text{H}]^+$, calculated: 542.1504, found: 542.1478. **HPLC** 98%, RT 10.875 min.

Synthesis of **13** (LUF7934)




8-Methoxy-2,4-dihydropyrido[2,1-f]purine-2,4-dione (**10**)

1 (5.0 g, 15.51 mmol, 1.0 eq) was suspended in EtOH (250 mL). $\text{Pd}(\text{OH})_2/\text{C}$ (2.2 g, 15.5 mmol, 1.0 eq) was added and the reaction was brought under a nitrogen atmosphere. Ammonium formate (6.6 g, 105 mmol, 4.6 eq) was added and the mixture was refluxed at 80 °C. Over a period of one week, ten portions of ammonium formate (6.6 g, 105 mmol, 4.6 eq) were gradually added, as well as one portion of extra $\text{Pd}(\text{OH})_2/\text{C}$ (2.20 g, 15.5 mmol, 1.0 eq). Afterwards, the mixture was cooled to rt and filtered over Celite. The residue was extracted five times with hot DMF (100 mL). The filtrates were combined and concentrated. The residue was purified by column chromatography (DCM:MeOH 90:10 $\rightarrow$ 80:2) to yield 3.0 g of crude mixture **10**. This compound was used in subsequent reaction steps without further purifications. LC-MS $[\text{ESI}+\text{H}]^+$: 233.00.




***Tert*-butyl (3-(8-methoxy-2,4-dioxo-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)carbamate (**11**)**

Crude **10** (1.57 g, 6.8 mmol, 1.0 eq) was dissolved in dry DMF (70 mL) and *tert*-butyl (3-bromopropyl)carbamate (1.61 g, 6.8 mmol, 1.0 eq) was added. The mixture was cooled to 0 °C and K₂CO₃ was added (1.40 g, 10.1 mmol, 1.5 eq). The mixture was allowed to warm up to rt overnight and was stirred for another 3 days. Due to the slow progress of the reaction, the mixture was heated at 40 °C and stirred for another 2 days. Extra *tert*-butyl (3-bromopropyl)carbamate was then added (0.32 g, 1.4 mmol, 0.2 eq), which resulted in the slow formation of double substituted **3** (as determined by LC-MS). The reaction was therefore stopped. EtOAc (180 mL) was added and the organic layer was washed with H₂O (3 x 180 mL) and brine (90 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH 98:2 → 95:5) to yield **11** (486 mg, 1.68 mmol, 25%). LC-MS [ESI+H]⁺: 390.15.



1-(3-Aminopropyl)-8-methoxy-3-(prop-2-yn-1-yl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (12**)**

(i) Propargylbromide (80% in toluene) (446 µL, 4.14 mmol, 3.0 eq) and DBU (0.619 mL, 4.14 mmol, 3.0 eq) were added to a mixture of **11** (536 mg, 1.38 mmol, 1.0 eq) in acetonitrile (7 mL), upon which the suspension became a clear solution. The mixture was stirred overnight and the next day H₂O (25 mL) was added. The aqueous layer was extracted with DCM (2 x 35 mL). The organic layers were combined, dried over MgSO₄, filtered and concentrated under reduced pressure. (ii) The resulting residue was dissolved in DCM (10 mL) and TFA (5 mL) was added. The mixture was stirred for 2 h and afterwards quenched by the addition of 2M NaOH (50 mL). The aqueous layer was extracted with EtOAc (2 x 50 mL). The organic layers were combined, dried with MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH 95:5 → 85:15) to yield **12** (300 mg, 0.92 mmol, 67%) as an off-white solid. **TLC** (DCM:MeOH 85:15 + 1% Et₃N): R_f = 0.67. **¹H NMR** (500 MHz, CD₃OD): δ [ppm] = 8.69 (d, *J* = 7.3 Hz, 1H), 6.99 (d, *J* = 2.5 Hz, 1H), 6.83 (dd, *J* = 7.4, 2.5 Hz, 1H), 4.70 (d, *J* = 2.4 Hz, 2H), 4.23 (t, *J* = 6.4 Hz, 2H), 3.90 (s, 3H), 2.99 (t, *J* = 7.2 Hz, 2H), 2.48 (t, *J* = 2.4 Hz, 1H), 2.15 (p, *J* = 6.8 Hz, 2H).



4-((3-(8-Methoxy-2,4-dioxo-3-(prop-2-yn-1-yl)-3,4-dihydropyrido[2,1-f]purin-1(2H)-yl)propyl)carbamoyl)benzenesulfonyl fluoride (13**) (LUF7934)**

EDC·HCl (347 mg, 1.81 mmol, 2.0 eq), 4-(fluorosulfonyl)benzoic acid (347 mg, 1.70 mmol, 1.9 eq) and DIPEA (387 µL, 2.26 mmol) were added to a solution of **12** (300 mg, 0.92 mmol, 1.0

eq) in dry DMF (6 mL). The mixture was stirred for 3 h, after which all starting material was consumed (as determined by TLC). DCM (50 mL) was added and the organic layer was washed with water (50 mL) and brine (50 mL), dried over MgSO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH 99:1 $\rightarrow$ 98:2) and (Pentane:EtOAc 1:1 $\rightarrow$ 0:1) to yield **13** (60 mg, 0.12 mmol, 13%) as a white solid. **TLC** (DCM:MeOH 99:1): R_f = 0.35. **^1H NMR** (500 MHz, CDCl_3): δ [ppm] = 8.85 (d, J = 7.3 Hz, 1H), 8.27 (t, J = 6.2 Hz, 1H), 8.24 (d, J = 8.3 Hz, 2H), 8.14 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 7.3, 2.5 Hz, 1H), 4.86 (d, J = 2.4 Hz, 2H), 4.37 (t, J = 6.0 Hz, 2H), 3.92 (s, 3H), 3.48 (q, J = 6.0 Hz, 2H), 2.21 (t, J = 2.4 Hz, 1H), 2.20 – 2.14 (m, 2H). **^{13}C NMR** (126 MHz, CDCl_3): δ [ppm] = 165.0, 162.5, 153.3, 151.5, 151.2, 149.9, 141.6, 135.4 (d, J = 25.4 Hz), 128.8, 128.7, 128.4, 108.6, 101.0, 95.1, 78.5, 71.0, 56.2, 41.2, 36.0, 30.6, 27.5. **^{19}F NMR** (471 MHz, CDCl_3): δ [ppm] = 65.71. **HRMS** (ESI, m/z): $[\text{M}+\text{H}]^+$, calculated: 514.1191, found: 514.1149. **HPLC** 100%, RT 10.077 min.

Biology

Ethics approval

The parts of the study involving human participants were reviewed and approved by Sanquin Institutional Ethical Committee (project number NVT0606.01). All blood samples were obtained after informed consent and according to the Declaration of Helsinki 1964. The patients and participants provided informed consent to participate in this study.

Cell lines

Chinese hamster ovary (CHO) cells stably expressing the human adenosine A_3 receptor (CHO hA_3 AR) were kindly provided by Prof. K.N. Klotz (University of Würzburg). CHO cells stably expressing the human adenosine A_1 receptor (CHO hA_1 AR) were kindly provided by Prof. S.J. Hill (University of Nottingham), human embryonic kidney 293 (HEK293) cells stably expressing the human adenosine A_{2A} receptor (HEK hA_{2A} AR) were kindly provided by Dr. J. Wang (Biogen) and CHO cells stably expressing the human A_{2B} receptor (CHO-spap- hA_{2B} AR) were kindly provided by S.J. Dowell (GlaxoSmithKline).

Radioligands

$[\text{}^3\text{H}]\text{PSB-11}$, specific activity 56 Ci/mmol, was a kind gift from Prof. C.E. Müller (University of Bonn). $[\text{}^3\text{H}]\text{DPCPX}$, specific activity 137 Ci/mmol, and $[\text{}^3\text{H}]\text{ZM241385}$, specific activity 50 Ci/mmol, were purchased from ARC Inc. and $[\text{}^3\text{H}]\text{PSB-603}$, specific activity 79 Ci/mmol, was purchased from Quotient BioResearch.

Chemicals

5'-(N-Ethylcarboxamido)adenosine (NECA), N^6 -Cyclopentyladenosine (CPA) and adenosine deaminase (ADA) were purchased from Sigma-Aldrich. ZM241385 was kindly provided by Dr. S.M. Poucher (AstraZeneca), CGS21680 was purchased from Ascent Scientific, PSB 1115 potassium salt was purchased from Tocris Bioscience and PSB-11 hydrochloride was purchased from Abcam Biochemicals. Bicinchoninic acid (BCA) protein assay reagents were purchased from Thermo Scientific. All click reagents (CuSO_4 , sodium ascorbate (NaAsc), Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), Cy5- N_3 and Azide-Fluor-545 (TAMRA- N_3) were purchased from Sigma-Aldrich. PierceTM ECL Western Blotting Substrate was ordered from Thermo Scientific. 4x Laemmli Sample Buffer was ordered from Bio-Rad. All other chemicals were of analytical grade and obtained from standard commercial sources.

Biologicals

PNGase (cat# V4831) was purchased from Promega (Leiden, The Netherlands). Rabbit anti-A₃AR antibody (cat# bs-1225R) was ordered from Thermo Scientific (Landsmeer, The Netherlands), rabbit anti-A₃AR PE conjugate (cat# orb495084) was ordered from Biorbyt (Huisen, The Netherlands), goat anti-rabbit-HRP antibody (cat# 115-035-003) was purchased from Brunschwig Chemie (Amsterdam, The Netherlands) and PE anti-human Siglec-8 Antibody (mouse IgG1 clone 7C9) (cat# 347104) was purchased from Biolegend (San Diego, CA, USA). Bovine Serum Albumin (BSA)(cat# 268131000) was purchased from Acros Organics (Geel, Belgium).

Cell culture and membrane preparation

CHO-hA₃AR, CHO-hA₁AR, CHO-hA_{2A}AR, CHO-spap-hA_{2B}AR and CHO-K1 cells were cultured as previously reported.^[50] Membranes were prepared in the following manner: cells were detached from plates by scraping in PBS (5 mL). The cells were collected and centrifuged (5 min, 1000 rpm). Supernatant was removed and cells were resuspended in ice-cold Tris-HCl buffer (pH 7.4). The cells were homogenized (Heidolph Diox 900 homogenizer) and the membranes were separated from the cytosolic fraction by centrifugation (20 min, 31000 rpm, 4°C) using a Beckman Optima LE-80 K ultracentrifuge. The pellet was resuspended in Tris-HCl buffer and the homogenization and centrifugation steps were repeated. The resulting pellet was resuspended in Tris-HCl buffer and ADA was added (0.8 U/mL) to break down endogenous adenosine. Total protein concentrations were determined using the BCA method.^[51]

Radioligand displacement assays

Single point assay on all four adenosine receptors

Membrane aliquots containing 15 µg (CHO-hA₃AR), 5 µg (CHO-hA₁AR) or 30 µg (HEK293hA_{2A}AR and CHO-spap-A_{2B}AR) of protein were resuspended in assay buffer (A₃AR: 50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1mM EDTA, 0.01% CHAPS; A₁AR and A_{2A}AR: 50 mM Tris-HCl, pH 7.4; A_{2B}AR: 50 mM Tris-HCl, pH 7.4, 0.1% CHAPS). Competing ligand (1 µM) and radioligand (A₃AR: 10 nM [³H]PSB-11; A₁AR: 1.6 nM [³H]DPCPX; A_{2A}AR: 1.7 nM [³H]ZM241385; A_{2B}AR: 1.5 nM [³H]PSB-603) were added and the samples were incubated in a total volume of 100 µL of the respective assay buffer for 30 min at 25 °C. Nonspecific binding was determined in the presence of 100 µM NECA (A₃AR), 100 µM CPA (A₁AR), 100 µM NECA (A_{2A}AR) and 10 µM ZM241385 (A_{2B}AR). Incubations were terminated by rapid vacuum filtration to separate the bound and free radioligand through prewetted 96-well GF/C filter plates using a PerkinElmer Filtermate-harvester. Filters were subsequently washed 12 times with ice-cold wash buffer (A₃AR: 50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1mM EDTA; A₁AR and A_{2A}AR: 50 mM Tris-HCl, pH 7.4; A_{2B}AR: 50 mM Tris-HCl, pH 7.4, 0.1% BSA). The plates were dried at 55 °C and MicroscintTM-20 cocktail (PerkinElmer) was added subsequently. After 3 h the filter-bound radioactivity was determined by scintillation spectrometry using a 2450 MicroBeta Microplate Counter (PerkinElmer).

Full curve assay on the adenosine A₃ receptor

Membrane aliquots containing 15 µg of protein (CHO-hA₃AR) were resuspended in assay buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1mM EDTA, 0.01% CHAPS). Competing ligand (concentrations ranging from 0.1 to 1000 nM) was added and pre-incubated with the membrane fractions for either 0 or 4 hours. Radioligand (10 nM [³H]PSB-11) was then added and incubated with the samples in a total volume of 100 µL of assay buffer for 30 min at 25 °C. Nonspecific binding was determined in the presence of 100 µM NECA. Incubations were

terminated by rapid vacuum filtration through prewetted 96-well GF/C filter plates using a PerkinElmer Filtermate-harvester. Filters were subsequently washed 12 times with ice-cold wash buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1 mM EDTA). The plates were dried at 55 °C and MicroscintTM-20 cocktail (PerkinElmer) was added subsequently. After 3 h the filter-bound radioactivity was determined using a Tri-Carb 2810TR Liquid Scintillation Analyzer (PerkinElmer).

Wash-out assay

200 µL assay buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1 mM EDTA and 0.01% CHAPS), 100 µL assay buffer containing competing ligand (final concentration: 1 µM) and 100 µL of CHO_hA₃AR membrane fractions (100 µg protein) were combined and pre-incubated for 2 h at 25 °C while shaking. The '4x washed' samples were centrifuged (5 min, 13000 rpm, 4 °C) and the supernatant removed. The resulting pellet was dissolved in 1 mL assay buffer and incubated for 10 min at 25 °C while shaking. The '4x washed' samples were then again centrifuged (2 min, 13000 rpm, 4 °C), the supernatant removed and the resulting pellet dissolved in 1 mL assay buffer. The latter washing steps were repeated two times (four times washing total) and the final pellet was dissolved in 300 µL assay buffer. Radioligand (10 nM [³H]PSB-11) in 100 µL assay buffer was added to all samples and the samples were incubated at 25 °C for 1 h. Nonspecific binding was determined in the presence of 100 µM NECA. Incubations were terminated by addition of 1 mL ice-cold washing buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 1 mM EDTA) and rapid vacuum filtration through prewetted 96-well GF/B filter plates using a Brandel harvester. Filters were subsequently washed 5 times with ice-cold wash buffer. The plates were dried under vacuum and MicroscintTM-20 cocktail (PerkinElmer) was added subsequently. After 3 h the filter-bound radioactivity was determined using a 2450 MicroBeta Microplate Counter (PerkinElmer).

Data analysis and statistics

Data analysis was performed using GraphPad Prism version 9.0.0 (San Diego, California USA). pIC₅₀ values were obtained by non-linear regression curve fitting and converted to pK_i values using the Cheng-Prusoff equation.^[52] As such, the K_D values of 1.6 nM of [³H]DPCPX at CHO_hA₁AR membranes and 1.7 nM of [³H]PSB603 at CHO-spap-hA_{2B}AR membranes were taken from previous experiments,^[53,54] while the K_D values of 1.0 nM of [³H]ZM241385 at HEK293hA_{2A}AR membranes and 17.3 nM of [³H]PSB-11 at CHO_hA₃AR membranes were taken from in-house determinations. Single point displacement values shown are mean percentages of two individual experiments performed in duplicate. All pK_i values shown are mean values ± SEM of three individual experiments performed in duplicate. Statistical analysis was performed using a one-way ANOVA test with multiple comparisons (**** p < 0.0001).

SDS-PAGE experiments

SDS-PAGE experiments using membranes

Membrane fractions were prepared as mentioned above and diluted to a concentration of 1 µg/µL. 18 µL of membrane fractions from either CHO_hA₃AR or CHO-K1 cells were taken. 1 µL of competing ligand (PSB-11, unless noted otherwise) was added (final concentration: 1 µM in 0.05% DMSO in assay buffer) and the samples were shaken for 30 min at rt. 1 µL of affinity-based probe was then added (final concentration: 50 nM in 0.05% DMSO in assay buffer, unless noted otherwise) and the samples were shaken for 1 h at rt. Deglycosylation was initiated by addition of 0.5 µL PNGaseF (5U), 0.5 µL MilliQ water for the control samples, and the samples were shaken for 1 h at rt. Click mix was freshly prepared by adding together: 5 parts 100 mM CuSO₄ in MilliQ, 3 parts 1 M NaAsc in MilliQ, 1 part 100 mM THPTA in MilliQ and 1 part 100 µM Cy5-N₃ in DMSO. 2.28 µL of click mix was added to the samples (final

concentration Cy5-N₃: 1 μ M in 1% DMSO in MilliQ) and the samples were shaken for 1 h at rt. Lastly 7.59 μ L of 4x Laemmli buffer was added and the samples were shaken for at least 1 h at rt. The samples were then loaded on gel (12.5% acrylamide) and run (180 V, 100 min). In-gel fluorescence was measured on a Bio-Rad Universal Hood III using Cy3 (605/50 filter) or Cy5 (695/55 filter) settings. Pageruler prestained protein ladder was used as molecular weight marker. After scanning, gels were either transferred to 0.2 μ M PVDF blots (Bio-Rad) using a Bio-Rad Trans-Blot Turbo system (2.5 A, 7 min) or stained with Coomassie Brilliant Blue.

SDS-PAGE experiments using live CHO cells

CHOA₃AR and CHO-K1 cells were cultured as mentioned above. Cells were grown to ~90% confluency in 10 cm ϕ plates. 10 plates were used per condition per experiment. Medium was removed and competing ligand (PSB-11, unless noted otherwise) in medium (final concentration: 1 μ M) was added. Cells were incubated for 1 h (37 °C, 5% CO₂). Medium was removed and affinity-based probe (final concentration: 50 nM in medium) was added. The cells were incubated for 1 h (37 °C, 5% CO₂) and washed with PBS to get rid of all the non-bound probe. Subsequently the membranes prepared and collected using the procedure as described above. Membrane aliquots were diluted to a concentration of 1 μ g/ μ L and 20 μ L was taken per sample. PNGase (0.5 μ L, 5U) or MilliQ was added and the samples were incubated 1 h at rt. Next, click mix was freshly prepared by adding together: 5 parts 100 mM CuSO₄ in MilliQ, 3 parts 1 M NaAsc in MilliQ, 1 part 100 mM THPTA in MilliQ and 1 part 100 μ M Cy5-N₃ in DMSO. 2.28 μ L of click mix was added per sample (final concentration Cy5-N₃: 1 μ M in 1% DMSO in MilliQ) and the samples were shaken for 1 h at rt. 7.59 μ L of 4x Laemmli buffer was added per sample and the samples were shaken for at least 1 h at rt. The samples were then loaded on gel (12.5% acrylamide) and run (180 V, 100 min). In-gel fluorescence was measured on a Bio-Rad Universal Hood III using Cy3 (605/50 filter) or Cy5 (695/55 filter) settings. Pageruler prestained protein ladder was used as molecular weight marker. After scanning, gels were either transferred to 0.2 μ M PVDF blots (Bio-Rad) using a Bio-Rad Trans-Blot Turbo system (2.5 A, 7 min) or stained with Coomassie Brilliant Blue.

Western blot experiments

Blots were blocked for 1 h at rt in 5% BSA in TBST. Primary antibody RabbitA₃AR (bs-1225R) 1:10.000 in 1% BSA in TBST was then added and the blots were incubated overnight at 4 °C. Blots were washed (3 x TBST) and incubated for 1 h at rt with secondary antibody goat-rabbit-HRP (115-035-003) 1:2.000 in 1% BSA in TBST. The blots were washed (2 x TBST and 1 x TBS) and activated by incubating 3 min in the dark using 1 mL of both reagents of PierceTM ECL Western Blotting Substrate. Blots were scanned on chemiluminescence and fluorescence using the Bio-Rad Universal Hood III.

Data Analysis and statistics

Gel images were analyzed using Image LabTM software version 6.0.1 (Bio-Rad). Quantification was done in the following manner: the area under the curve (AUC) of the bands was selected using the 'Lane Profile' tab and the adjusted volumes were taken. The adjusted volumes were then corrected for the amount of protein in each lane, using the adjusted total lane volumes of the Coomassie stained gels. The volume of the band at 55 kDa in the molecular weight marker (PageRuler Plus) was set to 100 (%) and the other bands were normalized accordingly. Further data analysis and statistics were carried out using Graphpad Prism. All given percentages are the mean values $\pm$ SEM of three individual experiments. Statistical analysis was performed using a one- or two-way ANOVA test with multiple comparisons (** $p < 0.001$; * $p < 0.01$; ns = not significant).

Confocal Microscopy Experiments

Probe binding and click reaction

CHO α A₃AR and CHO-K1 cells were cultured in a 96-well plate. Upon reaching a confluency of about 90%, the medium was replaced by medium containing PSB-11 (final concentration: 1 μ M) or 1% DMSO (control) and the cells were pre-incubated for 30 min (37 °C and 5% CO₂). The medium was then replaced with medium containing LUF7960 (final concentration: 50 nM) or 1% DMSO (vehicle) and the cells were incubated for 60 min (37 °C and 5% CO₂). The cells were washed with PBS to remove unbound probe and afterwards fixed using a 4% PFA in 10% formalin solution (15 min, rt). The remaining fixative was removed by washing with PBS and subsequently with 20 mM glycine in PBS. The cells were permeabilized by incubation in 0.1% saponin in PBS (10 min, rt). Remaining saponin was removed by a PBS wash and the cells were stored at 4 °C until further usage. At the day of imaging, PBS was removed and the cells were incubated for 1 h in freshly prepared click mix (100 μ L 100 mM CuSO₄ in MilliQ, 100 μ L 1 M NaAsc in MilliQ, 100 μ L mM THPTA in MilliQ, 9.66 mL HEPES pH 7.4 and 40 μ L 1 mM TAMRA-N₃ in DMSO, added in the respective order). Remaining click mix was removed by washing with PBS, incubating for 30 min with 1% BSA in PBS and again washing with PBS. Cells were stored in 300 nM DAPI in PBS prior to imaging.

Image acquisition

Microscopy was performed on a Nikon Eclipse Ti2 C2+confocal microscope (Nikon, Amsterdam, The Netherlands) and this system included an automated xy-stage, an integrated Perfect Focus System (PFS) and 408 and 561 lasers. The system was controlled by Nikon's NIS software. All images were acquired using a 20x objective with 0.75 NA at a resolution of 1024x1024 pixels. The acquisition of 9 fields of view per well was done automatically using the NIS Jobs functionality. Representative images are shown in the figure and were created by using OMERO.^[46]

Quantification

CellProfiler (version 2.2.0) was used to create a binary image of the DAPI channel and to propagate the cytoplasmic area based on the DAPI binary. An overlay of the binary cytoplasm/TAMRA channel was generated to quantify per segmented pixel the TAMRA intensity. The sum of these intensities in the cytoplasm mask is referred to as the integrated TAMRA intensity in the cytoplasm. Segmentation results were further processed using Excel while GraphPadPrism 9 was used for data visualization and statistics.

Flow Cytometry Experiments

Click reaction between LUF7960 and Cy5-N₃

Click mix was freshly prepared by combining in a 2 mL Eppendorf tube: 250 μ L of 100 mM CuSO₄ in MilliQ, 150 μ L of 1 M NaAsc in MilliQ, 50 μ L of 100 mM THPTA in MilliQ and 50 μ L of 50 μ M Cy5-N₃ in DMSO, in the same respective order. Next, 500 μ L of 2 μ M LUF7960 in 1% DMSO in MilliQ was added and the mixture was incubated for 1 h at rt while shaking (1000 rpm). The mixture was desalted using a Waters Sep-Pak C18 column (WAT054945). Briefly, the mixture was loaded on the column and washed three times with 1 mL MilliQ. The product (LUF7960-Cy5) was then eluted using 1 mL of acetonitrile. The solvent was removed using an Eppendorf Concentrator Plus and the residue was dissolved in DMSO to obtain the stock concentrations of LUF7960-Cy5.

Flow cytometry experiments using CHO cells

CHOhA₃AR and CHO-K1 cells were cultured as mentioned above. The cells were detached using Trypsin and centrifuged (5 min, 1500 rpm). The pellet was dissolved in medium (1 mL), the cells were counted and the solution was diluted to 1.000.000 cells/mL. 100 µL of cell solution was added to each well of a 96-well plate. The plate was centrifuged (5 min, 1500 rpm) and the medium was replaced by medium containing PSB-11 (final concentration: 1 µM) or 1% DMSO (control). Cells were resuspended and incubated for 30 min (37 °C, 5% CO₂). The plate was centrifuged (5 min, 1500 rpm) and the medium was replaced by medium containing pre-clicked LUF7960-Cy5 (final concentration: 50 nM). Cells were resuspended and incubated for 1 h (37 °C, 5% CO₂). The plate was centrifuged (5 min, 1500 rpm), the medium was removed and 1% BSA in PBS containing rabbitαhA₃AR PE conjugate (1:500) was added. Cells were resuspended and incubated for 30 min at 4 °C. The cells were washed with 1% BSA in PBS to remove unbound probe and antibody and resuspended in 1% BSA in PBS. Cells were measured using a Cytoflex S (Beckman and Coulter, USA) and data was analyzed with FlowJo™ v10.0.7 (BD Life Sciences). The gating strategy is shown in Figure S3.

Purification of human granulocytes

Primary cells were isolated from human blood collected from healthy donors. Polymorphonuclear neutrophils (PMNs) were isolated using a Percoll gradient with a density of 1.076 g/ml.^[55] Erythrocytes were lysed with isotonic NH₄Cl/KHCO₃, washed twice in PBS and resuspended in HEPES buffer (20 mM HEPES, 132 mM NaCl, 6.0 mM KCl, 1.0 mM CaCl₂, 1.0 mM MgSO₄, 1.2 mM KH₂PO₄, 5.5 mM glucose and 0.5% (w/v) human serum albumin, pH 7.4). Eosinophils were isolated from the PMNs as described before.^[56]

Flow cytometry experiments using human granulocytes

100 µL of PMNs or purified eosinophils (2·10⁶ cells/mL) in HEPES buffer was incubated with 50 µL of PSB-11 (final concentration: 1 µM) or 1% DMSO (control) in HEPES buffer for 30 min at rt. 50 µL of pre-clicked LUF7960-Cy5 (final concentration: 50 nM) or 1% DMSO (vehicle) was added and the samples were incubated for 1 h at rt. The samples were then added to a 96 well-plate and centrifuged (5 min, 1500 rpm, 4 °C). The supernatant was removed and the pellet was suspended in a solution containing antibody (Siglec-8 PE conjugate 1:100) in 0.5% HSA in PBS. The samples were incubated for 30 min at 4 °C, centrifuged (5 min, 1500 rpm, 4 °C) and washed once with 0.5% HSA in PBS. The final pellet was suspended in 0.5% HSA in PBS. Cells were measured on a Canto II flow cytometer (BD, Franklin Lakes, NJ, USA) and analyzed with FACSDiva software. The gating strategy is shown in Figure S3.

Data analysis and statistics

Histograms (Figure 7B and D) were created using FlowJo. Further data analysis was performed using Graphpad Prism. MFI values shown are mean ± SEM from three individual experiments performed in duplicate (Figure 7A) or four individual experiments (Figure 7C). Statistical analysis was performed using a one-way ANOVA test with multiple comparisons (**** p < 0.0001; *** p < 0.001; ** p < 0.01; ns = not significant).

Computational Methods

Docking of the affinity-based probes in an hA₃AR homology model

The Alphafold model of the hA₃AR was retrieved from the GPCRdb.^[35,36,57] This structure was prepared using the protein preparation wizard in Maestro (version 13.3, 2022-3, Schrödinger, LLC)^[58] and the four compounds (compound **5**, **9** and **13** from this work and **17b** (LUF7602) from Yang et al.)^[59] were prepared using LigPrep (Schrödinger, LLC).^[60] Compound **17b** (LUF7602) was docked in the receptor model using the covalent binding protocol,^[61] and consecutively energy minimized using MacroModel (Schrödinger, LLC). The alkyne moiety was introduced on each of the exit vectors in 3D and subsequently subjected to an energy minimization step using MacroModel. Each of the resulting energy minimized structures was visualized using PyMOL (The PyMOL Molecular Graphics System, version 1.2r3pre, Schrödinger, LLC).

Author Contributions

B.L.H.B., I.M.S. and J.S. synthesized compounds. R.L. performed radioligand displacement experiments. B.L.H.B. and J.S. performed SDS-PAGE experiments. W.J. performed molecular docking experiments. B.L.H.B. and S.L.D. performed confocal microscopy experiments. S.L.D. carried out confocal microscopy data analysis. B.L.H.B. and A.T.J.T. performed flow cytometry experiments and carried out flow cytometry data analysis. T.W.K., G.J.P.W., L.H.H., A.P.I.J. and D.v.d.E. supervised the project.

References

- [1] B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, J. Linden, *Pharmacol Rev* **2001**, *53*, 527–552.
- [2] B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, C. E. Müller, *Pharmacol Rev* **2011**, *63*, 1–34.
- [3] A. P. IJzerman, K. A. Jacobson, C. E. Müller, B. N. Cronstein, R. A. Cunha, *Pharmacol Rev* **2022**, *74*, 340–372.
- [4] L. Antonioli, P. Pacher, G. Haskó, *Trends Pharmacol Sci* **2022**, *43*, 43–55.
- [5] C. Cekic, J. Linden, *Nat Rev Immunol* **2016**, *16*, 177–192.
- [6] C. Mazziotto, J. C. Rotondo, C. Lanzillotti, G. Campione, F. Martini, M. Tognon, *Oncogene* **2022**, *41*, 301–308.
- [7] Y. Kohno, J. Xiao-Duo, S. D. Mawhrter, M. Koshiba, K. A. Jacobson, *Blood* **1996**, *88*, 3569–3574.
- [8] B. A. M Walker, M. A. Jacobson, D. A. Knight, C. A. Salvatore, T. Weir, D. Zhou, T. R. Bai, *Am J Respir Cell Mol Biol* **1997**, *16*, 531–537.
- [9] M. G. Bouma, T. M. M. A. Jeunhomme, D. L. Boyle, M. A. Dentener, N. N. Voitenok, F. A. J. M. van den Wildenberg, W. A. Buurman, *The Journal of Immunology* **1997**, *158*, 5400–5408.
- [10] J. R. Fozard, H.-J. Pfannkuche, H.-J. Schuurman, *Eur J Pharmacol* **1996**, *298*, 293–297.
- [11] D. van der Hoeven, T. C. Wan, J. A. Auchampach, *Mol Pharmacol* **2008**, *74*, 685–696.
- [12] R. Corriden, T. Self, K. Akong-Moore, V. Nizet, B. Kellam, S. J. Briddon, S. J. Hill, *EMBO Rep* **2013**, *14*, 726–732.
- [13] Y. Chen, R. Corriden, Y. Inoue, L. Yip, N. Hashiguchi, A. Zinkernagel, V. Nizet, P. A. Insel, W. G. Junger, *Science (1979)* **2006**, *314*, 1792–1795.
- [14] K. F. Alsharif, M. R. Thomas, H. M. Judge, H. Khan, L. R. Prince, I. Sabroe, V. C. Ridger, R. F. Storey, *Vascul Pharmacol* **2015**, *71*, 201–207.
- [15] K. A. Jacobson, S. Merighi, K. Varani, P. A. Borea, S. Baraldi, M. Aghazadeh Tabrizi, R. Romagnoli, P. G. Baraldi, A. Ciancetta, D. K. Tosh, Z.-G. Gao, S. Gessi, *Med Res Rev* **2018**, *38*, 1031–1072.
- [16] C. T. Leung, A. Li, J. Banerjee, Z.-G. Gao, T. Kambayashi, K. A. Jacobson, M. M. Civan, *Purinergic Signal* **2014**, *10*, 465–475.
- [17] C. K. Goth, U. E. Petäjä-Repo, M. M. Rosenkilde, *ACS Pharmacol Transl Sci* **2020**, *3*, 237–245.
- [18] M. Jo, S. T. Jung, *Exp Mol Med* **2016**, *48*, e207.
- [19] A. J. Vernall, L. A. Stoddart, S. J. Briddon, S. J. Hill, B. Kellam, *J Med Chem* **2012**, *55*, 1771–1782.
- [20] E. Kozma, T. S. Kumar, S. Federico, K. Phan, R. Balasubramanian, Z.-G. Gao, S. Paoletta, S. Moro, G. Spalluto, K. A. Jacobson, *Biochem Pharmacol* **2012**, *83*, 1552–1561.
- [21] E. Kozma, E. T. Gizewski, D. K. Tosh, L. Squarcialupi, J. A. Auchampach, K. A. Jacobson, *Biochem Pharmacol* **2013**, *85*, 1171–1181.
- [22] A. J. Vernall, L. A. Stoddart, S. J. Briddon, H. W. Ng, C. A. Laughton, S. W. Doughty, S. J. Hill, B. Kellam, *Org Biomol Chem* **2013**, *11*, 5673–5682.
- [23] L. A. Stoddart, A. J. Vernall, J. L. Denman, S. J. Briddon, B. Kellam, S. J. Hill, *Chem Biol* **2012**, *19*, 1105–1115.
- [24] L. A. Stoddart, A. J. Vernall, S. J. Briddon, B. Kellam, S. J. Hill, *Neuropharmacology* **2015**, *98*, 68–77.
- [25] S. Federico, E. Margiotto, S. Paoletta, S. Kachler, K.-N. Klotz, K. A. Jacobson, G. Pastorin, S. Moro, G. Spalluto, *Medchemcomm* **2019**, *10*, 1094–1108.
- [26] S. Federico, E. Margiotto, S. Moro, E. Kozma, Z.-G. Gao, K. A. Jacobson, G. Spalluto, *Eur J Med Chem* **2020**, *186*, 111886.

- [27] K. S. Toti, R. G. Campbell, H. Lee, V. Salmaso, R. R. Suresh, Z. G. Gao, K. A. Jacobson, *Purinergic Signal* **2022**, DOI 10.1007/s11302-022-09873-3.
- [28] M. Macchia, F. Salvetti, S. Bertini, V. di Bussolo, L. Gattuso, M. Gesi, M. Hamdan, K.-N. Klotz, T. Laragione, A. Lucacchini, F. Minutolo, S. Nencetti, C. Papi, D. Tusciano, C. Martini, *Bioorg Med Chem Lett* **2001**, *11*, 3023–3026.
- [29] D. Greenbaum, K. F. Medzihradsky, A. Burlingame, M. Bogoy, *Chem Biol* **2000**, *7*, 569–581.
- [30] Y. Liu, M. P. Patricelli, B. F. Cravatt, *Proceedings of the National Academy of Sciences* **1999**, *96*, 14694–14699.
- [31] X. Yang, J. P. D. Van Veldhoven, J. Offringa, B. J. Kuiper, E. B. Lenselink, L. H. Heitman, D. Van Der Es, A. P. IJzerman, *J Med Chem* **2019**, *62*, 3539–3552.
- [32] V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, *Angewandte Chemie - International Edition* **2002**, *41*, 2596–2599.
- [33] C. W. Tornøe, C. Christensen, M. Meldal, *Journal of Organic Chemistry* **2002**, *67*, 3057–3064.
- [34] G. Tomasello, I. Armenia, G. Molla, *Bioinformatics* **2020**, *36*, 2909–2911.
- [35] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Zidek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohli, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli, D. Hassabis, *Nature* **2021**, *596*, 583–589.
- [36] M. Varadi, S. Anyango, M. Deshpande, S. Nair, C. Natassia, G. Yordanova, D. Yuan, O. Stroe, G. Wood, A. Laydon, A. Zidek, T. Green, K. Tunyasuvunakool, S. Petersen, J. Jumper, E. Clancy, R. Green, A. Vora, M. Lutfi, M. Figurnov, A. Cowie, N. Hobbs, P. Kohli, G. Kleywegt, E. Birney, D. Hassabis, S. Velankar, *Nucleic Acids Res* **2022**, *50*, D439–D444.
- [37] D. K. Tosh, M. Chinn, L. S. Yoo, D. W. Kang, H. Luecke, Z.-G. Gao, K. A. Jacobson, *Bioorg Med Chem* **2010**, *18*, 508–517.
- [38] P. N. H. Trinh, D. J. W. Chong, K. Leach, S. J. Hill, J. D. A. Tyndall, L. T. May, A. J. Vernall, K. J. Gregory, *J Med Chem* **2021**, *64*, 8161–8178.
- [39] B. L. H. Beekens, Ç. Koç, R. Liu, B. I. Florea, S. E. Le Dévédec, L. H. Heitman, A. P. IJzerman, D. Van Der Es, *ACS Chem Biol* **2022**, *17*, 3131–3139.
- [40] X. Yang, T. J. M. Michiels, C. de Jong, M. Soethoudt, N. Dekker, E. Gordon, M. van der Stelt, L. H. Heitman, D. van der Es, A. P. IJzerman, *J Med Chem* **2018**, *61*, 7892–7901.
- [41] E.-M. Priego, J. von Frittag Drabbe Kuenzel, A. P. IJzerman, M.-J. Camarasa, M.-J. Pérez-Pérez, *J Med Chem* **2002**, *45*, 3337–3344.
- [42] W. Jespers, A. C. Schiedel, L. H. Heitman, R. M. Cooke, L. Kleene, G. J. P. van Westen, D. E. Gloriam, C. E. Müller, E. Sotelo, H. Gutiérrez-de-Terán, *Trends Pharmacol Sci* **2018**, *39*, 75–89.
- [43] C. E. Müller, M. Thorand, R. Qurishi, M. Diekmann, K. A. Jacobson, W. L. Padgett, J. W. Daly, *J Med Chem* **2002**, *45*, 3440–3450.
- [44] T. M. Palmer, J. L. Benovic, G. L. Stiles, *J Biol Chem* **1995**, *270*, 29607–29613.
- [45] T. M. Palmer, G. L. Stiles, *Mol Pharmacol* **2000**, *57*, 539–545.
- [46] C. Allan, J.-M. Burel, J. Moore, C. Blackburn, M. Linkert, S. Loynton, D. MacDonald, W. J. Moore, C. Neves, A. Patterson, M. Porter, A. Tarkowska, B. Loranger, J. Avondo, I. Lagerstedt, L. Lianas, S. Leo, K. Hands, R. T. Hay, A. Patwardhan, C. Best, G. J. Kleywegt, G. Zanetti, J. R. Swedlow, *Nat Methods* **2012**, *9*, 245–253.
- [47] J. J. Reeves, C. A. Harris, B. P. Hayes, P. R. Butchers, M. J. Sheehan, *Inflammation Research* **2000**, *49*, 666–672.
- [48] L. M. Gazoni, D. M. Walters, E. B. Unger, J. Linden, I. L. Kron, V. E. Laubach, *Journal of Thoracic and Cardiovascular Surgery* **2010**, *140*, 440–446.
- [49] Y. Inoue, Y. Chen, M. I. Hirsh, L. Yip, W. G. Junger, *Shock* **2008**, *30*, 173–177.
- [50] T. Amelía, J. P. D. van Veldhoven, M. Falsini, R. Liu, L. H. Heitman, G. J. P. van Westen, E. Segala, G. Verdon, R. K. Y. Cheng, R. M. Cooke, D. van der Es, A. P. IJzerman, *J Med Chem* **2021**, *64*, 3827–3842.
- [51] P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goetze, B. J. Olson, D. C. Klenk, *Anal Biochem* **1985**, *150*, 76–85.
- [52] Y.-C. Cheng, W. H. Prusoff, *Biochem Pharmacol* **1973**, *22*, 3099–3108.
- [53] A. Kourounakis, C. Visser, M. De Groote, A. P. IJzerman, *Biochem Pharmacol* **2001**, *61*, 137–144.
- [54] A. Vlachodimou, H. de Vries, M. Pasoli, M. Goudswaard, S.-A. Kim, Y.-C. Kim, M. Scottichini, M. Marshall, J. Linden, L. H. Heitman, K. A. Jacobson, A. P. IJzerman, *Biochem Pharmacol* **2022**, *200*, 115027.
- [55] A. J. Verhoeven, M. L. J. van Schaik, D. Roos, R. S. Weening, *Blood* **1988**, *71*, 505–507.
- [56] L. Koenderman, P. T. M. Kok, M. L. Hamelink, A. J. Verhoeven, P. L. B. Bruijnzeel, *J Leukoc Biol* **1988**, *44*, 79–86.
- [57] J. Caroli, A. Mamyrbekov, A. A. Kermani, **2023**, *51*, 395–402.
- [58] G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman, *Journal of Computer-Aided Molecular Design* **2013**, *27*, 221–234.
- [59] X. Yang, J. P. D. Van Veldhoven, J. Offringa, B. J. Kuiper, E. B. Lenselink, L. H. Heitman, D. Van Der Es, A. P. IJzerman, *J Med Chem* **2019**, *62*, 3539–3552.
- [60] J. R. Greenwood, D. Calkins, A. P. Sullivan, J. C. Shelley, *Journal of Computer-Aided Molecular Design* **2010**, *24*, 591–604.
- [61] K. Zhu, K. W. Borrelli, J. R. Greenwood, T. Day, R. Abel, R. S. Farid, E. Harder, *Journal of Chemical Information and Modeling* **2014**, *54*, 1932–1940.

